{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:57:38Z","timestamp":1792155458802,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/aims<\/jats:title>\n                <jats:p>The dapivirine vaginal ring is a self-administered, women-initiated, discreet, long-acting HIV-1 prevention option for women. It was found to be safe and effective in healthy HIV-negative women who adhered to product use instructions, and has been approved for use in women aged 18 and older in some African countries. A qualitative study was conducted to explore participants\u2019 and their male partners\u2019 discussions on accidental\/purposeful vaginal ring removals during The Ring Study (IPM 027 clinical trial).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were collected via in-depth interviews and focus group discussions with female trial participants and their male partners, from seven research centres in South Africa and Uganda. Data were thematically analysed using NVivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>More participants reported purposeful ring removals than accidental expulsions. Various factors influenced purposeful ring removal \u2013 including individual (discomfort during use\/sex and to clean it), partner (to show them, because of discomfort during sex, to test if partners could feel it, and concerns of harm), organisational (doctor\u2019s request), and socio-cultural (rumours about sickness and infertility). Some described their own ring use removal, others discussed why other participants removed their rings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Vaginal ring adherence is critical to improve and support product efficacy. Counselling on vaginal anatomy, vaginal ring insertion and importance of adherence is important to minimise vaginal ring removal. Couples counselling is also important to facilitate support and long-term vaginal ring adherence behaviour. Understanding factors influencing vaginal ring adherence is important for tailoring and targeting messages to support correct and consistent vaginal ring use as it is made available to the public.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-024-18795-1","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T08:02:01Z","timestamp":1717142521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027)"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-7560","authenticated-orcid":false,"given":"Cecilia","family":"Milford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariska","family":"Ramlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rorisang","family":"Mofokeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letitia","family":"Rambally Greener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annal\u00e9ne","family":"Nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte","family":"Malherbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"18795_CR1","doi-asserted-by":"crossref","unstructured":"Griffin JB, Ridgeway K, Montgomery E, Torjesen K, Clark R, Peterson J et al. Vaginal ring acceptability and related preferences among women in low- and middle-income countries: a systematic review and narrative synthesis. PLoS ONE. 2019;14.","DOI":"10.1371\/journal.pone.0224898"},{"issue":"1","key":"18795_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.fertnstert.2004.01.025","volume":"82","author":"NJ Alexander","year":"2004","unstructured":"Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E. Why consider vaginal drug administration? Fertil Steril. 2004;82(1):1\u201312.","journal-title":"Fertil Steril"},{"issue":"7","key":"18795_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1089\/jwh.2021.0121","volume":"31","author":"ST Roberts","year":"2022","unstructured":"Roberts ST, Hawley I, Luecke E, Mensch B, Wagner T, Hoesley C, et al. Acceptability and preference for 3-month versus 1-month vaginal rings for HIV-1 risk reduction among participants in a phase 1 trial. J Women\u2019s Health. 2022;31(7):1029\u201339.","journal-title":"J Women\u2019s Health"},{"key":"18795_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.contraception.2021.10.001","volume":"106","author":"K Ridgeway","year":"2021","unstructured":"Ridgeway K, Montgomery ET, Smith K, Torjesen K, van der Straten A, Achilles SL, Griffin JB. Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world. Contraception. 2021;106:16\u201333.","journal-title":"Contraception"},{"key":"18795_CR5","doi-asserted-by":"publisher","first-page":"e25283","DOI":"10.1002\/jia2.25283","volume":"22","author":"ET Montgomery","year":"2019","unstructured":"Montgomery ET, Beksinska M, Mgodi N, Schwartz K, Weinrib R, Brown EN, et al. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro clinical crossover study. J Int AIDS Soc. 2019;22:e25283.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"18795_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/jwh.2021.0394","volume":"31","author":"EE Tolley","year":"2022","unstructured":"Tolley EE, Zissette S, Taylor J, Hanif HJ, Schwarz S, Thurman J. Acceptability of a Long-Acting, Multipurpose Vaginal Ring: findings from a phase I Trial in the U.S. and Dominican Republic. J Women\u2019s Health. 2022;31(9):1343\u201352.","journal-title":"J Women\u2019s Health"},{"issue":"4","key":"18795_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/QAI.0000000000002590","volume":"86","author":"K Naidoo","year":"2021","unstructured":"Naidoo K, Mansoor LE, Katz AWK, Garcia M, Browne EN, Kemigisha D, et al. Qualitative perceptions of dapivirine vaginal ring adherence and drug level feedback following an open-label extension trial. J Acquir Immunce Defic Syndr. 2021;86(4):90\u20136.","journal-title":"J Acquir Immunce Defic Syndr"},{"issue":"3","key":"18795_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/sifp.12209","volume":"53","author":"DM Harris","year":"2022","unstructured":"Harris DM, Dam A, Morrison K, Mann C, Jackson A, Bledsoe S, et al. Barriers and enablers influencing women\u2019s adoption and continuation of vaginally inserted contraceptive methods: a Literature Review. Stud Fam Plann. 2022;53(3):455\u201390.","journal-title":"Stud Fam Plann"},{"key":"18795_CR9","doi-asserted-by":"crossref","unstructured":"Montgomery ET, Stadler J, Naidoo S, Katz AW, Laborde N, Garcia M et al. Reasons for non-adherence to the dapivirine vaginal ring: results of the MTN-032\/AHA study. AIDS. 2018;32(11).","DOI":"10.1097\/QAD.0000000000001868"},{"issue":"1","key":"18795_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/03630242.2019.1607803","volume":"60","author":"Z Duby","year":"2019","unstructured":"Duby Z, Katz A, Musara P, Nabukeera J, Zimba CC, Woeber K, et al. The state of mind tells me it\u2019s dirty: menstrual shame amongst women using a vaginal ring in Sub Saharan Africa. Women Health. 2019;60(1):72\u201386.","journal-title":"Women Health"},{"key":"18795_CR11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, Bekker L-G, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133\u201343.","journal-title":"N Engl J Med"},{"key":"18795_CR12","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a Vaginal Ring containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016;375:2121\u201332.","journal-title":"N Engl J Med"},{"key":"18795_CR13","unstructured":"Microbicide Trials Network (MTN). Questions and answers: HOPE - HIV open-label prevention extension study2019 6 February 2024. https:\/\/www.mtnstopshiv.org\/news\/questions-and-answers-hope-hiv-open-label-prevention-extension-study."},{"key":"18795_CR14","unstructured":"World Health Organization (WHO). European Medicines Agency (EMA) approval of the dapivirine ring for HIV prevention for women in high HIV burden settings2020 14 January 2023. https:\/\/www.who.int\/news\/item\/24-07-2020-european-medicines-agency-(ema)-approval-of-the-dapivirine-ring-for-hiv-prevention-for-women-in-high-hiv-burden-settings."},{"key":"18795_CR15","unstructured":"International Partnership for Microbicides (IPM). South Africa Approves Dapivirine Vaginal Ring for Use by Women2022 14 January 2023. https:\/\/www.ipmglobal.org\/content\/south-africa-approves-dapivirine-vaginal-ring-use-women#:~:text=(March%2011%2C%202022)%E2%80%94,to%20reduce%20their%20HIV%20risk."},{"key":"18795_CR16","unstructured":"The Global PrEP Tracker [Internet]. [cited 8 August 2023]. https:\/\/data.prepwatch.org\/."},{"key":"18795_CR17","unstructured":"Phillips H. PrEP vaginal ring \u2018as effective\u2019 as PrEP pills in Zimbabwe study 2023 18 July 2023. https:\/\/www.beintheknow.org\/news-and-blogs\/prep-vaginal-ring-effective-prep-pills-zimbabwe-study."},{"key":"18795_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-7622-5-8","volume":"5","author":"HA Weiss","year":"2008","unstructured":"Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol. 2008;5:1\u20137.","journal-title":"Emerg Themes Epidemiol"},{"issue":"8","key":"18795_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/09540121003623719","volume":"22","author":"RA Ferrer","year":"2010","unstructured":"Ferrer RA, Morrow KM, Fisher WA, Fisher JD. Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials. AIDS Care. 2010;22(8):997\u20131005.","journal-title":"AIDS Care"},{"issue":"4","key":"18795_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.bpobgyn.2012.01.010","volume":"26","author":"SS Abdool Karim","year":"2012","unstructured":"Abdool Karim SS, Baxter C. Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynecol. 2012;26(4):427\u201339.","journal-title":"Best Pract Res Clin Obstet Gynecol"},{"issue":"12","key":"18795_CR21","doi-asserted-by":"publisher","first-page":"E779","DOI":"10.1016\/S2352-3018(23)00227-8","volume":"10","author":"G Nair","year":"2023","unstructured":"Nair G, Celum C, Szydlo D, Brown ER, Akello CA, Nakalega R, et al. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Lancet HIV. 2023;10(12):E779\u201389.","journal-title":"Lancet HIV"},{"issue":"8","key":"18795_CR22","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","volume":"31","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159\u201367.","journal-title":"AIDS"},{"issue":"6","key":"18795_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/COH.0b013e3283590632","volume":"7","author":"BS Mensch","year":"2012","unstructured":"Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS. 2012;7(6):534\u201341.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"18795_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10461-022-03745-y","volume":"27","author":"K Naidoo","year":"2023","unstructured":"Naidoo K, Katz AW, Morgan G, Reddy K, Soto-Torres L, Naidoo S, Mansoor LE. Efficacy and action of the dapivirine vaginal ring as understood by women participating in an open-label extension study. AIDS Behav. 2023;27(1):75\u201381.","journal-title":"AIDS Behav"},{"key":"18795_CR25","unstructured":"Scheckter R, Mack N, Amico R, MacQueen K. Pathways to high adherence: An adherence support manual for vaginal ring trials2016 27 June 2023. https:\/\/www.fhi360.org\/resource\/pathways-high-adherence-adherence-support-manual-vaginal-ring-trials."},{"issue":"2","key":"18795_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10461-017-1977-1","volume":"22","author":"ND Laborde","year":"2018","unstructured":"Laborde ND, Pleasants E, Reddy K, Atujuna M, Nakyanzi T, Chitukuta M, et al. Impact of the Dapivirine Vaginal Ring on sexual experiences and intimate partnerships of women in an HIV Prevention Clinical Trial: managing Ring Detection and Hot Sex. AIDS Behav. 2018;22(2):437\u201346.","journal-title":"AIDS Behav"},{"key":"18795_CR27","unstructured":"Nikolopoulou K. What is social desirability bias? Definitions and examples2023 16 August 2023. https:\/\/www.scribbr.com\/research-bias\/social-desirability-bias\/."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18795-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-18795-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18795-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T08:06:03Z","timestamp":1717142763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-18795-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["18795"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-18795-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from multiple local ethics committees including: Pharma-Ethics (Ref: 11074447), University of the Witwatersrand\u2019s Human Research Ethics Committee (Wits HREC; Ref: 110810), Medical Research Council\/Uganda Virus Institute Research Ethics Committee (MRC\/UVRI REC, Ref: GC\/127\/13\/03\/33), University of Cape Town Human Research Ethics Committee (UCT HREC, Ref: 273\/2013) and University of Pretoria Research Ethics Committee (UPREC, Ref: 388\/2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable, individual data\/images not used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All participants provided written informed consent to participate in the focus group discussions or in-depth interviews.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare that there is no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1458"}}